Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from EKSO BIONICS ( (EKSO) ) is now available.
On May 1, 2026, Ekso Bionics entered into a securities purchase agreement with Applied Parent for a private investment in public equity, under which the company will issue 1,311,407 unregistered common shares at $12.01 per share, raising approximately $15.75 million. The APLD Parent PIPE Investment is scheduled to close at 3:01 a.m. ET on May 5, 2026, immediately before the closing of a broader business combination, and Lake Street Capital Markets will receive a 5% cash fee, or about $0.75 million, for acting as exclusive placement agent.
The transaction, executed under Securities Act exemptions based on investor representations, is structured to support the pending business combination and Nasdaq listing plans, though it remains subject to customary closing conditions and regulatory risks. The company highlights that failure to close the PIPE or business combination, adverse market conditions, listing delays, or potential litigation could materially affect outcomes, underscoring execution risk for shareholders and other stakeholders.
The most recent analyst rating on (EKSO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EKSO BIONICS stock, see the EKSO Stock Forecast page.
Spark’s Take on EKSO Stock
According to Spark, TipRanks’ AI Analyst, EKSO is a Neutral.
The score is held down primarily by weak financial performance (large losses, cash burn, shrinking equity) and a highly dilutive, control-shifting corporate event. Technicals are a relative positive with an uptrend and moderate momentum, but valuation is constrained by negative earnings and no dividend support.
To see Spark’s full report on EKSO stock, click here.
More about EKSO BIONICS
Ekso Bionics operates in the medical technology industry, developing and commercializing exoskeleton systems and related robotic solutions aimed at rehabilitation and mobility support. Its primary products are used by healthcare providers and patients to assist with neurorehabilitation, gait training, and physical recovery, positioning the company within the broader market for advanced assistive and rehabilitation robotics.
Average Trading Volume: 91,421
Technical Sentiment Signal: Buy
Current Market Cap: $42.01M
See more insights into EKSO stock on TipRanks’ Stock Analysis page.